Astellas, seagen and merck announce fda acceptance of supplemental biologics license applications for padcev® (enfortumab vedotin-ejfv) with keytruda® (pembrolizumab) for the first-line treatment of certain patients with locally advanced or metastatic urothelial cancer

– this combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting – – fda granted the applications priority review with a pdufa date of april 21, 2023 – tokyo, bothell, wash. and rahway, n.j.
SGEN Ratings Summary
SGEN Quant Ranking